Saby George, MD | Authors

May 04, 2022

Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.

April 27, 2022

Expert perspectives on optimal genomic testing practices in patients with prostate cancer.

April 27, 2022

Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.

April 20, 2022

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

April 20, 2022

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

April 13, 2022

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

April 13, 2022

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

April 06, 2022

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

April 06, 2022

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

June 23, 2016

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.